Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Senti Biosciences, Inc. incurred convertible notes of $10.0 million with Celadon Partners SPV 24 affiliate at will not bear any interest unless an event of default has occurred maturing six months after the closing date of the Initial Notes.
- Instrument
- convertible notes
- Principal
- $10.0 million
- Counterparty
- Celadon Partners SPV 24 affiliate
- Rate
- will not bear any interest unless an event of default has occurred
- Maturity
- six months after the closing date of the Initial Notes
- Event
- incurrence
Exact text from the filing
the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Senti Biosciences, Inc. issued Senior Secured Convertible Notes convertible into shares of common stock of the Company, Senti Biosciences, and Senti Holdings of convertible note to Celadon Partners SPV 24 for $40.0 million aggregate principal amount (initial tranche of $10.0 million).
- Security
- convertible note
- Shares
- Senior Secured Convertible Notes convertible into shares of common stock of the Company, Senti Biosciences, and Senti Holdings
- Purchaser
- Celadon Partners SPV 24
- Consideration
- $40.0 million aggregate principal amount (initial tranche of $10.0 million)
Exact text from the filing
On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Senti Biosciences, Inc. entered into Securities Purchase Agreement with an entity affiliated with Celadon Partners SPV 24 valued at $40.0 million (effective 2026-04-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an entity affiliated with Celadon Partners SPV 24
- Value
- $40.0 million
- Effective
- 2026-04-27
Exact text from the filing
On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.
View on SEC.gov